InvestSMART

Radiopharm Theranostics Limited (ASX: RAD) - Announcements

Current share price for RAD : $0.004 0.001 (20%)+

ASX company news and announcements for Radiopharm Theranostics Limited (RAD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Radiopharm Theranostics Limited (RAD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Radiopharm Theranostics Limited (RAD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Radiopharm Theranostics Limited (RAD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$19 Target market determination (TMD) 20 Oct 2025 4:59PM $0.029 $0.004 fallen by 86.21%
$19 Prospectus 20 Oct 2025 4:52PM $0.029 $0.004 fallen by 86.21%
$19 Investor Presentation - Clinical Update and Capital Raising 20 Oct 2025 9:33AM $0.037 $0.004 fallen by 89.19%
$19 RAD Provides Positive Clinical Updates Across Four Programs 20 Oct 2025 9:28AM $0.037 $0.004 fallen by 89.19%
$19 Proposed issue of securities - RAD 20 Oct 2025 9:26AM $0.037 $0.004 fallen by 89.19%
$19 Proposed issue of securities - RAD 20 Oct 2025 9:25AM $0.037 $0.004 fallen by 89.19%
$19 Proposed issue of securities - RAD 20 Oct 2025 9:25AM $0.037 $0.004 fallen by 89.19%
$19 RAD completes A$35 M Placement and launches A$5 M SPP 20 Oct 2025 9:25AM $0.037 $0.004 fallen by 89.19%
$19 Trading Halt 15 Oct 2025 5:43PM $0.037 $0.004 fallen by 89.19%
$19 Notification regarding unquoted securities - RAD 7 Oct 2025 11:13AM $0.038 $0.004 fallen by 89.47%
$19 Radiopharm received approval for RAD 202 trial acceleration 1 Oct 2025 9:18AM $0.029 $0.004 fallen by 86.21%
$19 Radiopharm Theranostics Partners with Starpharma on Research 30 Sep 2025 9:47AM $0.029 $0.004 fallen by 86.21%
$19 SPL:Research & Option Agreement with Radiopharm Theranostics 30 Sep 2025 9:45AM $0.029 $0.004 fallen by 86.21%
$19 Corporate Governance Statement and Appendix 4G 17 Sep 2025 9:43AM $0.032 $0.004 fallen by 87.50%
$19 Annual Report and Form 20-F 17 Sep 2025 9:40AM $0.032 $0.004 fallen by 87.50%
$19 Pivalate (Brain Mets) key opinion leader webinar 15 Sep 2025 8:56AM $0.031 $0.004 fallen by 87.10%
$19 Appendix 4E and Preliminary Final Report 29 Aug 2025 11:37AM $0.028 $0.004 fallen by 85.45%
$19 Appendix 4E and Preliminary Final Report 29 Aug 2025 11:37AM $0.028 $0.004 fallen by 85.45%
$19 Radiopharm to host key opinion leader webinar series 21 Aug 2025 9:38AM $0.025 $0.004 fallen by 83.67%
$19 Notification regarding unquoted securities - RAD 1 Aug 2025 2:59PM $0.023 $0.004 fallen by 82.61%
$19 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jul 2025 9:55AM $0.022 $0.004 fallen by 81.82%
$19 RAD receives IND approval from US FDA for Betabart (RV-01) 28 Jul 2025 8:26AM $0.023 $0.004 fallen by 82.61%
$19 Dr Oliver Sartor appointed to RAD Scientific Advisory Board 22 Jul 2025 8:30AM $0.023 $0.004 fallen by 82.61%
$19 Radiopharm Receives $4.5M R&D Tax Incentive 16 Jul 2025 9:01AM $0.022 $0.004 fallen by 81.82%
$19 RAD and Cyclotek Sign Supply Agreement for 161Tb-KLK3-mAb 24 Jun 2025 9:35AM $0.023 $0.004 fallen by 82.61%

101 - 125 of 632 results

Page 5 of 26

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.